140 related articles for article (PubMed ID: 35113412)
21. Advanced or metastatic pancreatic cancer: molecular targeted therapies.
Bayraktar S; Rocha-Lima CM
Mt Sinai J Med; 2010; 77(6):606-19. PubMed ID: 21105124
[TBL] [Abstract][Full Text] [Related]
22. Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review.
Kono M; Fujii T; Lim B; Karuturi MS; Tripathy D; Ueno NT
JAMA Oncol; 2017 Sep; 3(9):1266-1273. PubMed ID: 28301631
[TBL] [Abstract][Full Text] [Related]
23. Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy.
Kasper S; Reis H; Ziegler S; Nothdurft S; Mueller A; Goetz M; Wiesweg M; Phasue J; Ting S; Wieczorek S; Even A; Worm K; Pogorzelski M; Breitenbuecher S; Meiler J; Paul A; Trarbach T; Schmid KW; Breitenbuecher F; Schuler M
Oncotarget; 2017 Jul; 8(28):45898-45917. PubMed ID: 28507280
[TBL] [Abstract][Full Text] [Related]
24. Antibody therapy in pancreatic cancer: mAb-ye we're onto something?
Boland AJ; O'Kane AA; Buick R; Longley DB; Scott CJ
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188557. PubMed ID: 33945846
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.
Javle MM; Shroff RT; Xiong H; Varadhachary GA; Fogelman D; Reddy SA; Davis D; Zhang Y; Wolff RA; Abbruzzese JL
BMC Cancer; 2010 Jul; 10():368. PubMed ID: 20630061
[TBL] [Abstract][Full Text] [Related]
26. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
27. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
28. Restoration of transforming growth factor-beta signaling enhances radiosensitivity by altering the Bcl-2/Bax ratio in the p53 mutant pancreatic cancer cell line MIA PaCa-2.
Ahmed MM; Alcock RA; Chendil D; Dey S; Das A; Venkatasubbarao K; Mohiuddin M; Sun L; Strodel WE; Freeman JW
J Biol Chem; 2002 Jan; 277(3):2234-46. PubMed ID: 11694525
[TBL] [Abstract][Full Text] [Related]
29. Biologic effect of neurogenesis in pancreatic cancer.
He D; Manzoni A; Florentin D; Fisher W; Ding Y; Lee M; Ayala G
Hum Pathol; 2016 Jun; 52():182-9. PubMed ID: 26980040
[TBL] [Abstract][Full Text] [Related]
30. ErbB receptors and signaling pathways in cancer.
Hynes NE; MacDonald G
Curr Opin Cell Biol; 2009 Apr; 21(2):177-84. PubMed ID: 19208461
[TBL] [Abstract][Full Text] [Related]
31. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
Belmont PJ; Jiang P; McKee TD; Xie T; Isaacson J; Baryla NE; Roper J; Sinnamon MJ; Lee NV; Kan JL; Guicherit O; Wouters BG; O'Brien CA; Shields D; Olson P; VanArsdale T; Weinrich SL; Rejto P; Christensen JG; Fantin VR; Hung KE; Martin ES
Sci Signal; 2014 Nov; 7(351):ra107. PubMed ID: 25389372
[TBL] [Abstract][Full Text] [Related]
32. Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC.
Ferrari P; Scatena C; Ghilli M; Bargagna I; Lorenzini G; Nicolini A
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163586
[TBL] [Abstract][Full Text] [Related]
33. KRAS-related proteins in pancreatic cancer.
Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
[TBL] [Abstract][Full Text] [Related]
34. Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.
Lim HJ; Crowe P; Yang JL
J Cancer Res Clin Oncol; 2015 Apr; 141(4):671-89. PubMed ID: 25146530
[TBL] [Abstract][Full Text] [Related]
35. Internal enhancement of DNA damage by a novel bispecific antibody-drug conjugate-like therapeutics via blockage of mTOR and PD-L1 signal pathways in pancreatic cancer.
Cao R; Song W; Ye C; Liu X; Li L; Li Y; Yao H; Zhou X; Li L; Shao R
Cancer Med; 2019 Feb; 8(2):643-655. PubMed ID: 30681288
[TBL] [Abstract][Full Text] [Related]
36. Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab.
Wang SE; Xiang B; Guix M; Olivares MG; Parker J; Chung CH; Pandiella A; Arteaga CL
Mol Cell Biol; 2008 Sep; 28(18):5605-20. PubMed ID: 18625725
[TBL] [Abstract][Full Text] [Related]
37. Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients.
Ghayad SE; Cohen PA
Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):29-57. PubMed ID: 19751211
[TBL] [Abstract][Full Text] [Related]
38. Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer.
Ebrahimi S; Hosseini M; Shahidsales S; Maftouh M; Ferns GA; Ghayour-Mobarhan M; Hassanian SM; Avan A
Curr Med Chem; 2017; 24(13):1321-1331. PubMed ID: 28176634
[TBL] [Abstract][Full Text] [Related]
39. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
[TBL] [Abstract][Full Text] [Related]
40. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis.
Newton HB
Expert Rev Anticancer Ther; 2004 Feb; 4(1):105-28. PubMed ID: 14748662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
